Intake device for delivery of fluid formulation into gastrointestinal tract

By generating a gas pressure-driven device in the GI lumen, the problem of poor enzyme decomposition and tolerance of macromolecular drugs in the gastrointestinal tract is solved, effective delivery and systemic intake of high-dose therapeutic agents are achieved, and compliance with drugs is improved sex.

CN118900707APending Publication Date: 2024-11-05RANI THERAPEUTICS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028656.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-21
Filing Date
2023-02-17
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing routes of administration such as intake and parenteral injection have problems such as enzyme decomposition of macromolecular drugs in the gastrointestinal tract, poor tolerance, pain and inconvenience in administration, limiting the delivery of high-dose therapeutic agents.

Method used

A device is designed to include an extensible member including a housing, piston, needle and membrane to move the piston by generating gas pressure within the GI lumen, the needle pierces the seal to deliver a fluid formulation, including doses up to 75 mg or more therapeutic agent.

Benefits of technology

Effective delivery of large doses of therapeutic agents is achieved, the disadvantages of conventional oral and parenteral administration routes are solved, allowing systemic intake and improving medication compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900707A_ABST
    Figure CN118900707A_ABST
Patent Text Reader

Abstract

A delivery assembly (300) for an ingestible device (200) for delivering a fluid formulation (317) into a GI lumen wall or surrounding tissue of a subject includes a housing (302), a piston, a needle (320), and a membrane (315). The housing (320) defines a chamber. A piston is movably disposed in the chamber. A needle (320) is coupled to the piston. The membrane is coupled to the piston such that the membrane and the piston cooperatively define a reservoir (315a) for containing a fluid formulation.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 312,354, filed on February 21, 2022, the entire contents of which are hereby incorporated by reference herein.

[0003] background

[0004] Therapeutic agents (such as drugs) can be administered to subjects by ingestion or by parenteral injection (e.g., subcutaneous, intramuscular or intravenous injection) to provide the desired therapeutic effect. However, these routes of administration have some disadvantages. For example, some therapeutic agents such as large (high) molecules are not suitable for delivery by ingestion because these molecules are enzymatically decomposed in the subject's gastrointestinal (GI) tract. Other types of therapeutic agents may originally be poorly tolerated in the GI tract, resulting in low systemic intake. For parenteral injection, subjects may experience pain and inconvenience in administration, which may significantly affect medication compliance and quality of life.

[0005] In order to address these shortcomings, ingestible devices have been proposed for oral delivery of therapeutic agents in solid form to the lumen wall of the GI tract or surrounding tissues. However, solid dosage forms may be limited to relatively small doses (e.g., a few milligrams). Therefore, the use of solid dosage forms may be disadvantageous for treatment regimens requiring higher doses due to, for example, frequency of administration, convenience, or cost.

[0006]

[0006] Therefore, there is a need for devices that are capable of delivering a wide range of dosages of therapeutic agents and that address one or more of the disadvantages associated with conventional oral and parenteral routes of administration.

[0007] Overview

[0008] Embodiments of the present disclosure generally relate to devices, assemblies and methods for delivering fluid preparations to the GI tract (e.g., GI cavity wall or surrounding tissue) of a subject. The device and assembly are configured to deliver up to about 250 microliters (μl) or more of fluid preparations, and the fluid preparations may include at least one therapeutic agent of up to about 75 milligrams (mg) or more dosages. In this way, disclosed devices, assemblies and methods may allow for the effective delivery of therapeutic agents in large dose ranges for most treatment regimens.

[0009] In one aspect, a delivery assembly for an ingestible device for delivering a fluid formulation into a GI luminal wall or surrounding tissue of a subject comprises a housing, a piston, a needle, and a membrane. The housing defines a chamber. The piston is movably disposed in the chamber. The needle is coupled to the piston. The membrane is coupled to the piston so that the membrane and the piston cooperatively define a reservoir for containing the fluid formulation.

[0010] On the other hand, an ingestible device for delivering a fluid formulation into a GI luminal wall or surrounding tissue of a subject comprises an expandable member and a delivery assembly coupled to the expandable member and disposed in the expandable member. The delivery assembly comprises a housing, a piston, a needle, a membrane, and a fluid formulation. The housing defines a chamber. The piston is movably disposed in the chamber. The needle is coupled to the piston. The membrane is coupled to the piston so that the membrane and the piston cooperatively define a reservoir. The fluid formulation is disposed in the reservoir and comprises at least one therapeutic agent.

[0011] In another aspect, a device includes a tissue piercing member having an elongated section and a tapered section extending from the elongated section to a distal end. The elongated section defines a longitudinal opening extending therethrough. The tapered section defines a slotted opening extending through a sidewall of the tapered section to the longitudinal opening. The slotted opening is used to discharge a fluid formulation from the tissue piercing member.

[0012] On the other hand, a method for delivering a fluid formulation to a subject's GI luminal wall or surrounding tissue comprises ingesting an ingestible device as described herein by the subject. The ingestible device comprises an expandable member and a delivery assembly coupled to the expandable member and disposed in the expandable member. The delivery assembly comprises a housing, a piston, a needle, a membrane, and a fluid formulation. The housing defines a chamber. The piston is movably disposed in the chamber. The needle is coupled to the piston. The membrane is coupled to the piston so that the membrane and the piston cooperatively define a reservoir. The fluid formulation is disposed in a reservoir and comprises at least one therapeutic agent.

[0013] On the other hand, a use of an ingestible device for delivering a fluid formulation to a subject's GI luminal wall or surrounding tissue comprises ingesting the ingestible device as described herein by the subject. The ingestible device comprises an expandable member and a delivery assembly coupled to the expandable member and disposed in the expandable member. The delivery assembly comprises a housing, a piston, a needle, a membrane, and a fluid formulation. The housing defines a chamber. The piston is movably disposed in the chamber. The needle is coupled to the piston. The membrane is coupled to the piston so that the membrane and the piston cooperatively define a reservoir. The fluid formulation is disposed in the reservoir and comprises at least one therapeutic agent.

[0014] In another aspect, a method of preparing an ingestible device for delivering a therapeutic agent to the GI lumen wall or surrounding tissue of a subject is provided, the method comprising filling a fluid formulation comprising the therapeutic agent into a delivery assembly as described herein.

[0015] In one or more embodiments of any one of the foregoing aspects, the expandable member comprises a balloon.

[0016] In one or more embodiments of any one of the preceding aspects, the device further comprises an ingestible housing, wherein the expandable member and the delivery assembly are disposed in the ingestible housing.

[0017] In one or more embodiments of any one of the foregoing aspects, the device further comprises a plurality of reactants disposed in the expandable member for generating gas pressure to expand the expandable member within the GI lumen. In one or more embodiments, the generated gas pressure is applied to the membrane to move the piston axially relative to the housing.

[0018] In one or more embodiments of any one of the preceding aspects, the piston further defines a needle cavity, and the needle is slidably coupled to the piston in the needle cavity.

[0019] In one or more embodiments of any of the preceding aspects, the delivery assembly further comprises a seal coupled to the piston between the needle lumen and the reservoir to define a substantially fluid-tight seal between the needle lumen and the reservoir.

[0020] In one or more embodiments of any of the foregoing aspects, the needle includes a first end configured to penetrate the GI lumen wall and a second end configured to pierce the seal in response to resistance applied to the needle from the GI lumen wall.

[0021] In one or more embodiments of any one of the preceding aspects, the membrane comprises a flexible material such that the generated gas pressure deforms the membrane to expel the fluid formulation through the needle when the needle pierces the seal.

[0022] In one or more embodiments of any of the preceding aspects, the device is configured such that the first end of the needle penetrates the GI lumen wall before the second end of the needle pierces the seal.

[0023] In one or more embodiments of any of the foregoing aspects, the device is configured such that penetration of the GI lumen wall by the first end of the needle occurs substantially simultaneously with piercing of the seal by the second end.

[0024] In one or more embodiments of any of the foregoing aspects, the needle is configured to pierce through the GI lumen wall into the peritoneum or peritoneal cavity of the subject to discharge the fluid formulation in the peritoneum or peritoneal cavity.

[0025] In one or more embodiments of any of the preceding aspects, the membrane has a surface profile that is complementary to an inner surface profile of a piston defining the reservoir.

[0026] In one or more embodiments of any of the preceding aspects, the reservoir defines a volume for accommodating up to about 250 μl of fluid. In one or more embodiments, the reservoir defines a volume for accommodating about 50 μl to about 200 μl of fluid.

[0027] In one or more embodiments of any one of the preceding aspects, the piston comprises a fill port for filling the reservoir with the fluid agent.

[0028] In one or more embodiments described in any one of the foregoing aspects, the delivery assembly further comprises a fluid formulation disposed in the reservoir, wherein the fluid formulation comprises at least one therapeutic agent. In one or more embodiments described in any one of the foregoing aspects, at least one therapeutic agent is selected from one or more of an immunosuppressive drug, a chemotherapeutic drug, a central nervous system (CNS) drug, an antidiabetic drug, an enzyme replacement therapy (ERT) drug, an antibody, a hormone, insulin, an incretin, or a combination thereof, or an oligonucleotide.

[0029] In one or more embodiments of any one of the preceding aspects, the tissue-piercing member further comprises a tip coupled to or integrally formed with the tapered section at the distal end. In one or more embodiments, the tip comprises a harder material than the material of the tissue-piercing member.

[0030] In one or more embodiments, the device is ingestible.

[0031] The foregoing general description and the following detailed description are provided by way of example and are intended to provide further explanation of the disclosure claimed without limiting the disclosure or the claims. Other objects, advantages and novel features will be apparent to those skilled in the art from the following brief description of the drawings and the detailed description of the disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 An embodiment of a device for delivering a fluid formulation to the GI tract of a subject is shown in block diagram form.

[0034] Figure 2 Shows Figure 1 A cross-sectional view of an embodiment of a device.

[0035] Figure 3 The delivery component is shown Figure 2 Detailed view of a portion of the device.

[0036] Figure 4 The device is shown in a second state when it has reached a desired location in the GI tract to deliver a fluid formulation. Figure 3 device.

[0037] Figure 5 Shown along Figure 3 A cross-sectional view taken along line 5-5.

[0038] Figure 6Methods of delivering a fluid formulation to the GI tract of a subject using the devices and assemblies of the present disclosure are presented.

[0039] Figure 7-Figure 8 A device suitable for use in the apparatus described herein (such as Figure 1 A tissue-piercing member used in an ingestible device.

[0040] Detailed Description

[0041] Before discussing the details of the apparatus, assemblies, and methods of the present disclosure, some generalizations are provided for the convenience of the reader.

[0042] When used in the present disclosure, the terms "eg, "," such as "," for example "," for an example "," for another example "," examples of "," by way of example ", and "etc." indicate that one or more non-limiting examples are listed preceding or following; it should be understood that other unlisted examples are also within the scope of the present disclosure.

[0043] As used herein, the singular terms "a", "an", and "the" may include plural references unless the context clearly dictates otherwise. Reference to an object in the singular is not intended to mean "one and only one" unless explicitly stated as such, but rather means "one or more".

[0044] As used herein, phrases in the form “A / B” or “A and / or B” mean (A), (B), or (A and B); phrases in the form “at least one of A, B, or C” mean (A), (B), (C), (A and B), (A and C), (B and C), or (A, B, and C).

[0045] The term "in an embodiment" or variations thereof (e.g., "in another embodiment" or "in an embodiment") refers to use in one or more embodiments herein, and in no case limits the scope of the present disclosure to only the illustrated and / or described embodiments. Thus, components shown and / or described herein with respect to an embodiment may be used in another embodiment (e.g., in another embodiment shown and described herein, or in another embodiment within the scope of the present disclosure and not shown and / or described herein).

[0046] The term "component" refers herein to an item in a group of one or more items, which together constitute the device, composition or system in question. A component may be a solid, powder, gel, plasma, fluid, gas or other composition. For example, a device may include a plurality of solid components that are assembled together to form the device, and may also include a liquid component disposed in the device. For another example, a composition may include a single component, or two or more components that are mixed together to prepare a composition. A composition may be in the form of a fluid, a slurry, a powder or a solid (e.g., in a concentrated or consolidated form, such as a tablet or microtablet). A device or system may include one or more compositions and / or one or more other components.

[0047] The term "design" or its grammatical variations (e.g., "designing" or "desinged") refers herein to properties that are intentionally incorporated based on estimates of, for example, tolerances (e.g., component tolerances and / or manufacturing tolerances) and environmental conditions expected to be encountered (e.g., temperature, humidity, external or internal environmental pressures, external or internal mechanical pressures, stresses from external or internal mechanical pressures, product age or shelf life, or if introduced into the body, physiology, body chemistry, biological composition of fluids or tissues, chemical composition of fluids or tissues, pH, species, diet, health, sex, age, ancestry, disease, or tissue damage); it is understood that actual tolerances and environmental conditions before and / or after delivery can affect the properties, such that different components, devices, compositions, or systems having the same design can have different actual values ​​for those properties. Design also includes changes or modifications before or after manufacture.

[0048] The term "structured" or its grammatical variations (e.g., "structure" or "structuring") as used herein refers to a component, device, composition or system manufactured according to a concept or design, or variations or modifications thereof (whether such variations or modifications occur before, during or after manufacture), whether or not such concept or design is recorded in writing.

[0049] Unless the context clearly dictates otherwise, the term "body" as used herein refers to the animal body.

[0050] The term "subject" refers herein to a body to which embodiments of the present disclosure are delivered or intended to be delivered. For example, in the case of humans, a subject may be a patient being treated by a health care professional. The terms "individual," "subject," and "patient" are used interchangeably herein and refer to any individual animal subject (e.g., cattle, dogs, cats, horses, or humans). In specific embodiments, the subject, individual, or patient is a human.

[0051] The term "fluid" herein refers to a liquid or a gas, and includes moisture and humidity. The term "fluid environment" herein refers to an environment in which one or more fluids are present.

[0052] The term "ingest" or grammatical variations thereof (e.g., "ingesting," "ingestion," or "ingested") refers herein to entry into the stomach, whether by swallowing or by other deposition into the stomach (e.g., endoscopic deposition into the stomach or deposition into the stomach via a port).

[0053] The term "degrade" or its grammatical variations (e.g., "degrading," "degraded," "degradable," and "degradation") herein refers to weakening, partial degradation, or complete degradation, such as by dissolution, chemical degradation (including biodegradation), decomposition, chemical modification, mechanical degradation, or disintegration, which also includes, but is not limited to, dissolution, fragmentation, deformation, shrinkage, or contraction. The term "non-degradable" refers to an expectation that degradation will be minimal or within some acceptable design percentage in the expected environment for at least the expected duration.

[0054] The term "degradation rate" or its grammatical variants (e.g., "rate of degradation") refers herein to the rate at which a material degrades. In particular embodiments, the designed degradation rate of a material can be defined by the rate at which the material is expected to degrade under expected conditions (e.g., under physiological conditions) at the target delivery site. The designed degradation time for a particular embodiment can refer to the designed time for complete degradation or the designed time for partial degradation sufficient to achieve the designed purpose (e.g., destruction). Thus, for example, the designed degradation time can be specific to a component and / or specific to the expected conditions at the target delivery site. The designed degradation time can be short or long and can be defined in terms of an approximate time, a maximum time, or a minimum time.

[0055] The term "substantially" is used herein to describe and account for small variations that may result from, for example, manufacturing or assembly processes. For example, when used in conjunction with a numerical value, the term may refer to a variation of less than or equal to ±10% of the value.

[0056] The term "lumen" herein refers to the interior space of a tubular structure. Examples of lumens in the body include arteries, veins, and tubular cavities within organs.

[0057] The term "luminal wall" refers to the wall of a lumen, wherein the wall includes all layers from the inner periphery to the outer periphery of the lumen, such as, for a lumen of the body, the mucosa, submucosa, muscularis, serosa, and outer wall of the lumen, as well as constituent blood vessels and tissues.

[0058] The term "gastrointestinal tract" or "GI tract" refers herein to the body's ingestion / excretion system including, for example, the mouth, pharynx, esophagus, stomach, pylorus, small intestine, cecum, large intestine, colon, rectum, anus, and valves or sphincters therebetween.

[0059] The term "GI lumen" generally refers to any lumen of the GI tract (eg, the lumen of the esophagus, stomach, small intestine, large intestine, or colon), and the term "GI lumen wall" refers to the luminal wall of the GI lumen.

[0060] As used herein, the terms "comprising," "comprise," "includes," and "including" are intended to mean that compositions and methods include the listed elements, but not excluding other elements.

[0061] With general reference to the accompanying drawings, embodiments of devices, assemblies and methods for delivering fluid preparations to the lumen wall or surrounding tissue (e.g., peritoneum or peritoneal cavity) of the GI tract of a subject are disclosed herein. The device is advantageously configured to substantially store one or more therapeutic agents in the fluid preparations in the GI tract for delivery to the GI lumen wall or its surrounding tissues. Delivery to the GI lumen wall or surrounding tissues may allow systemic intake of one or more therapeutic agents in the fluid preparations. In addition, for most treatment regimens, the preparations in fluid form may allow delivery of one or more therapeutic agents in a wide range of dosages (e.g., up to about 75 mg or more).

[0062] As discussed below, the disclosed devices and assemblies can deliver a variety of different types of therapeutic agents, such as macromolecules that are not typically suitable for delivery via ingestion. In this way, the disclosed devices, assemblies, and methods can address many of the drawbacks associated with conventional oral and parenteral routes of administration.

[0063] Figure 1 An example of a device 100 according to one or more embodiments of the present disclosure is shown in block diagram form. The device 100 includes a housing 102, an optional outer coating 104, an expandable member 106, a release member 108, and a delivery assembly 110. The delivery assembly 110 includes a housing 112, a membrane 114, a fluid formulation 116, a piston 118, and a needle 120.

[0064] According to non-limiting examples, the shell 102 (or alternatively the shell 102 and / or the outer coating 104) can be degraded at a desired position in the GI tract (e.g., stomach or small intestine) of the subject to deliver the fluid formulation 116, as described in more detail below. As described in more detail below, in response to at least partial degradation of the shell 102 and / or the outer coating 104, the release member 108 is activated to cause a chemical reaction in the expandable member 106, resulting in the formation of gas to cause the expandable member 106 to expand. The expansion of the expandable member 106 in the GI lumen causes the delivery assembly 110 to be positioned close to (e.g., adjacent to or in contact with) the lumen wall. When the internal pressure generated by the gas in the expandable member 106 reaches a threshold value (e.g., when the expandable member 106 expands), the gas pressure applied to the film 114 causes the piston 118 to move relative to the housing 112 and push the needle 120 toward the GI lumen wall. The GI lumen wall applies resistance to the needle 120 to move the piston 118 relative to the needle 120, so that the needle 120 pierces the seal on the piston 118 to allow the fluid formulation 116 to flow to the needle 120. Upon piercing the seal, the gas pressure exerted on the membrane 114 causes the membrane 114 to expel the fluid formulation 116 through the needle 120 and into the GI lumen wall or its surrounding tissue.

[0065] The housing 102 and outer coating 104 (if present) are configured to allow ingestion of the device 100 and to temporarily protect the contents of the device 100 from degradation within one or more portions of the GI tract of a subject. The housing 102 can take a variety of different forms and shapes, such as a swallowable capsule (e.g., a size 00 capsule, a size 000 capsule, or other size capsule), or any other structure suitable for ingestion by a subject and that can house or contain one or more of the components of the device 100 (e.g., at least the expandable member 106, the release member 108, and the delivery assembly 110). In one or more embodiments, the housing 102 includes two or more segments coupled (e.g., press-fit) together to define the housing 102. For example, the housing 102 can be configured as a capsule including a first segment that at least partially overlaps a second segment in a press-fit arrangement to define the housing 102. The first segment and the second segment can be removably coupled together to allow separation of the two segments. In one or more embodiments, expandable member 106, release 108, and delivery assembly 110 are all configured to be housed within the interior of housing 102. Release 108 may alternatively be positioned outside the interior of housing 102, such as on an exterior portion of housing 102.

[0066] In one or more embodiments, the housing 102 can degrade under certain conditions. In addition, different portions of the housing 102 can be configured to degrade under different conditions or at different degradation rates, depending on the target site within the GI tract to which the fluid formulation 116 is to be delivered. For example, a portion or all of the housing 102 can include a material that degrades in water (e.g., in the presence of water in the form of moisture or humidity in the surrounding environment, such as in the body), and / or when exposed to a pH level above a particular threshold or within a particular range (e.g., a pH level associated with a desired location and portion of the GI tract, such as a pH level associated with a target site within the GI tract for delivery of the fluid formulation 116).

[0067] Optional outer coating 104 optionally covers a portion or all of shell 102. Outer coating 104 can include a single layer or multiple layers. Each layer can be formed by the same material or different materials. In one or more embodiments, outer coating 104 can be degraded under certain conditions, as described above with reference to shell 102. The example of outer coating 104 is an enteric coating, such as an enteric coating that degrades at a given rate in water and / or degrades when exposed to a solution with a pH level higher than a specific threshold or within a specific range. Another example of outer coating 104 is a protective coating (e.g., wax), such as a coating that protects a portion of the outer surface of shell 102 from contact with a fluid or tissue (e.g., body tissue or fluid).

[0068] In one or more embodiments, degradation of the shell 102 and / or outer coating 104 allows fluid (e.g., bodily fluids in the stomach or intestines) to enter the interior of the shell 102 / outer coating 104 to activate the release member 108. Alternatively, the release member 108 can be positioned on an exterior portion of the shell 102, and degradation of the outer coating 104 can expose the release member 108 on the surface of the shell 102 to facilitate activation of the release member 108. Alternatively, the release member 108 can be positioned on a portion of the shell 102 without the outer coating 104, and the release member 108 can be configured to degrade at a different rate and / or under different conditions than the shell 102 in the GI tract.

[0069] The shell 102 and / or the outer coating 104 can define one or more degradation zones for localized degradation of the shell 102 and / or the outer coating 104, for example, to allow controlled degradation and separation of the shell 102. For example, the outer coating 104 can be selectively applied only to certain areas of the shell 102 (e.g., on the ends of the shell 102) to expose selected portions of the shell 102 (e.g., the middle portion of the shell 102 between the ends), thereby defining areas of the shell 102 that can degrade at a faster rate and / or earlier than other areas of the shell 102. Such controlled degradation of the shell 102 can allow for more consistent separation of the shell 102, thereby allowing the fluid formulation 116 to be delivered into the GI lumen wall.

[0070] Expandable member 106 is a flexible and adjustable structure. In one or more embodiments, expandable member 106 is configured to expand from a collapsed state (e.g., folded, rolled up, flattened) to an expanded state for delivery of fluid formulation 116 in the desired position of the GI lumen. Expandable member 106 can have various shapes, sizes and configurations for temporary storage in shell 102 and for deployment in the lumen of the GI tract of a subject. Expandable member 106 can be configured as a balloon, bellows / accordion structure or any other structure that can be adjusted from a collapsed state to an expanded state.

[0071] Expandable member 106 defines the internal volume of the various components for accommodating device 100. For example, expandable member 106 may include (e.g., comprise) one or more reactants temporarily separated from each other in the internal volume. The internal volume is configured to promote the chemical reaction caused by mixing reactants together (e.g., in response to the activation of release member 108), to form gas, and then cause the expansion of expandable member 106. Expandable member 106 may also include a structure for deflation of expandable member 106 to promote expandable member 106 to be discharged from a subject when delivering fluid preparation 116. Expandable member 106 is configured to stretch the amount limited when expanding without perforation.

[0072] Expandable member 106 can be formed by one or more materials.Examples of suitable materials for expandable member 106 include hydroxypropyl methylcellulose (HPMC), polyvinyl acetate (PVA), lactide, glycolide, lactic acid, glycolic acid, p-dioxanone, trimethylene carbonate, caprolactone and mixtures and copolymers thereof.Expandable member 106 can include one or more layers of material.Expandable member 106 can be an integral structure.In other embodiments, expandable member 106 can be composed of one or more segments that are connected (for example, sealed or sutured) together.

[0073] Release member 108 is a chemical, mechanical, electrical, electromechanical, electrochemical, chemomechanical or electromechanical chemical structure. Release member 108 is configured to cause expansion of expandable member 106 when release member 108 is activated. In one or more embodiments, release member 108 is configured to be activated (e.g., degraded, released, moved, opened) in response to conditions in the GI tract. For example, release member 108 can be configured to degrade in water so that release member 108 can degrade when in contact with fluid in the GI tract. For another example, release member 108 can be configured to degrade at or above a specific pH level or within a pH level range associated with a position in the GI tract (e.g., pH in the stomach, pH in the intestine). In these and other embodiments, release member 108 can be made of a biodegradable material (such as an enteric material).

[0074] Additionally or alternatively, release 108 can be configured as a latch, clip, cap, plug, coating, or any other structure that moves, opens, or otherwise releases in response to conditions in the GI tract. Release 108 can be formed from a single material or a combination of materials. Release 108 can include one or more components. In embodiments where multiple components are included in release 108, the components can be co-located (e.g., coaxially) or can be physically separated from each other.

[0075] The delivery assembly 110 is a chemical, mechanical, electrical, electromechanical, electrochemical, chemomechanical or electromechanical chemical structure. In one or more embodiments, the delivery assembly 110 may include a housing 112, a membrane 114, a fluid formulation 116, a piston 118 and a needle 120. In other embodiments, the delivery assembly 110 may include a housing 112, a membrane 114, a fluid formulation 116 and a piston 118 without a needle 120. In these embodiments, the delivery assembly 110 may be configured to deliver the fluid formulation 116 with a fluid jet through a nozzle or opening on the housing 112, wherein the fluid jet has sufficient velocity to penetrate the GI luminal wall for delivering the fluid formulation 116.

[0076] The delivery assembly 110 is configured to be coupled to the expandable member 106 and (partially or completely) disposed in the expandable member 106. The delivery assembly 110 is also configured to deliver a fluid formulation 116 to the GI lumen wall or surrounding tissue in response to expansion of the expandable member 106. The device 100 may include one or more delivery assemblies 110 coupled to the expandable member 106 to allow delivery of one or more fluid formulations.

[0077] The housing 112 is configured to be coupled to the expandable member 106 and (partially or completely) disposed in the expandable member 106. The housing 112 defines one or more chambers for movably receiving the piston 118 and the needle 120 or a piston without a needle. The housing 112 is configured to allow gas pressure from within the expandable member 106 to be applied to the membrane 114 to cause the piston 118 and the needle 120 to move axially relative to the housing 112. The housing 112 may include one or more components. In embodiments where multiple components are included in the housing 112, the components may be co-located or may be physically separated from each other.

[0078] Film 114 is a flexible structure. Film 114 is connected to piston 118. Film 114 and piston 118 cooperatively define a reservoir for accommodating fluid preparation 116. Reservoir can be limited to accommodate a volume of up to about 250 μl or more fluids (including 250 μl of fluid). Reservoir can be limited to accommodate a volume of about 50 μl to about 200 μl fluids (including 50 μl to 250 μl of fluids, such as 50 μl, 100 μl, 150 μl or 200 μl (or any value therebetween) of fluid), or can accommodate 200 μl or 250 μl (or any value therebetween) of fluid. Film 114 is also configured to respond to the pressure (e.g., from the gas generated in expandable member 106) applied on the outer surface of film 114 by fluid preparation 116 from reservoir to needle 120.

[0079] Film 114 can have any suitable shape, such as cylindrical, elliptical, spherical, cubic or other shapes. Film 114 can be formed by flexible or pliable material or otherwise include flexible or pliable material, to allow film 114 to be deformed (for example, pressure makes it bend / flex) to discharge fluid preparation 116. The example of suitable material for film 114 includes polymeric material (for example, polyethylene terephthalate (PET)) or other flexible materials with sufficiently low moisture and gas permeability characteristics to be used together with fluid preparation 116. Film 114 can be formed by a combination of single material or material. In addition, film 114 can include one or more layers of material. Film 114 can be an integral structure. In other embodiments, film 114 can include multiple sections that are connected (for example, sealed or sewn) together to limit film 114. Film 114 can include one or more components. In the embodiment of film 114, including multiple components, components can be co-located or can be physically separated from each other.

[0080] Fluid formulation 116 is a formulation comprising one or more components, wherein the formulation is intended for treatment, diagnosis or other biological purposes. Fluid formulation 116 is in the form of a fluid, such as a liquid, slurry, gel, suspension (including colloidal suspension), gas, powder or any combination thereof. The fluid formulation 116 includes one or more components, which include one or more therapeutic agents, such as proteins, peptides, polypeptides, antibodies, drugs (e.g., selected from one or more of immunosuppressive drugs (e.g., adalimumab), chemotherapeutic drugs, central nervous system (CNS) drugs (e.g., anti-Parkinson's agents, antiemetics), anti-diabetic drugs (e.g., metformin), enzyme replacement therapy (ERT) drugs), hormones (e.g., parathyroid hormone (PTH), follicle stimulating hormone (FSH) and analogs thereof), insulin, incretins or combinations thereof (e.g., GLP-1, GLP-2, GIP, glucagon, PYY and analogs thereof), oligonucleotides (e.g., antisense oligonucleotides (ASOs), RNA interference (RNAi), aptamer RNA), DNA or siRNA transcripts, cells, cytotoxic agents, vaccines or other prophylactic agents, nutrients, vasodilators or vasoconstrictors, delivery enhancers, delay agents, excipients, diagnostic agents, or substances for cosmetic purposes. The fluid formulation 116 may include a therapeutically effective amount of one or more therapeutic agents as well as other components (eg, excipients) in suitable amounts to achieve a desired therapeutic effect in a subject.

[0081] The piston 118 is movably (e.g., slidably) disposed in the housing 120. The piston 118 includes one or more cavities that cooperate with the membrane 114 to define a reservoir for containing the fluid formulation 116. The piston 118 is also configured to engage with the needle 120 to allow the needle 120 to move relative to the piston 118 to selectively control the flow of the fluid formulation 116 from the reservoir to the needle 120. The piston 118 is also configured to advance the needle 120 into the GI luminal wall or surrounding tissue in response to sufficient pressure applied to the piston 118 (e.g., via gas pressure applied to the membrane 114). The piston 118 may include one or more components. In embodiments where a plurality of components are included in the piston 118, the components may be co-located or may be physically separated from each other.

[0082] Needle 120 is connected to piston 118 and is configured to penetrate GI luminal wall or its surrounding tissue. Needle 120 can have the length of the desired depth that is enough to penetrate into experimenter's GI luminal wall or surrounding tissue. For example, needle 120 can have the length that is enough to penetrate and pass through GI luminal wall and enter experimenter's peritoneum or peritoneal cavity to discharge fluid preparation 116 therein. In one or more embodiments, needle 120 is movable relative to piston 118. In other embodiments, needle 120 is fixed relative to piston 118. Needle 120 comprises the passage for receiving fluid preparation 116 from reservoir and the opening for fluid preparation 116 to be discharged into GI luminal wall or surrounding tissue.

[0083] Needle 120 can be at least partially or completely degradable, so that needle 120 can be degraded in the GI lumen or surrounding components after fluid formulation 116 is delivered. Suitable materials for needle 120 can include, for example, polyethylene oxide (PEO), magnesium, polymer materials or other materials or material combinations. Needle 120 may include one or more components. In the embodiment where multiple components are included in needle 120, the components can be co-located or can be physically separated from each other. In other embodiments, needle 120 can be substantially non-degradable or can include substantially non-degradable parts. In any embodiment, and particularly in the embodiment where needle 120 is substantially non-degradable, delivery assembly 110 can be equipped with a return spring or other biasing structure to allow needle 120 to retract from the GI lumen wall in housing 112 to prevent damage to the subject.

[0084] One or more components of the device 100 (e.g., housing 102, outer coating 104, expandable member 106, release member 108, delivery assembly 110) can be formed from or otherwise include one or more biodegradable materials to promote degradation of such components, e.g., to allow passage through the remainder of the subject's intestinal tract following delivery of the fluid formulation 116. Examples of biodegradable materials that may be suitable for use with the various components of the device 100 include, e.g., hydroxypropyl methylcellulose (HPMC), polyvinyl acetate (PVA), lactide, glycolide, lactic acid, glycolic acid, p-dioxanone, trimethylene carbonate, caprolactone, and mixtures and copolymers thereof.

[0085] The foregoing description is an overview of the ingestible device 100. The following references Figure 2-Figure 8 The description of FIG. 1 relates to examples of various features and aspects of the device 100. These examples are intended to illustrate the device 100 rather than to limit the device 100.

[0086] refer to Figure 2, shows a cross-sectional view of a device 200 (an embodiment of device 100) in an unfolded and / or unrolled state. Device 200 is shown without housing 102 and / or optional outer coating 104. However, it should be appreciated that device 200 can be folded, rolled, and / or otherwise manipulated to be disposed within housing 102 (optionally, provided with outer coating 104) to allow ingestion of device 200 and subsequent delivery into the GI tract.

[0087] Device 200 includes an expandable member in the form of a balloon 202 (an embodiment of expandable member 106), a deflation valve 212, a reactant reservoir 214 containing a first reactant 215, a release member 216 (an embodiment of release member 108), a second reactant 217 and a delivery component 300 (an embodiment of delivery component 110).

[0088] Still reference Figure 2 The balloon 202 includes an inflatable segment 204, a deflated segment 205, a lower segment 206, and an elongated segment 210 extending between the inflatable segment 204 and the deflated segment 205. The lower segment 206 extends downward between the inflatable segment 204 and the deflated segment 205 (at Figure 2 215 and 217). The various segments of the balloon 202 cooperatively define an interior 202a for accommodating the various components of the device 200. As described below, the balloon 202 is configured to expand at a desired location within the lumen of the GI tract (e.g., stomach, intestine) in response to the formation of gas by a chemical reaction between the first reactant 215 and the second reactant 217 within the interior 202a. In this manner, the balloon 202 can facilitate the delivery of the fluid formulation 317 (an embodiment of the fluid formulation 116) from the delivery assembly 300 to the GI lumen wall or surrounding tissues.

[0089] The balloon 202 has a size and shape that occupies a space in the GI lumen when the balloon 202 is inflated to allow for delivery of the fluid formulation 317 into the GI lumen wall. For example, when the balloon 202 is inflated, the periphery of the balloon 202 (e.g., the periphery of the lower segment 206 and the elongated segment 210) is pushed against the surface of the lumen wall. The pressure applied by the balloon 202 is sufficient to temporarily hold the balloon 202 relative to the lumen wall to deliver the fluid formulation 317. Depending on the inner circumference of the lumen delivery site, when the balloon 202 is inflated, the lower segment 206 can remain partially folded or can be fully extended. For example, if the lumen is relatively large and there are no obstructions that impede the expansion of the balloon 202, the balloon 202 will assume a fully inflated configuration with the lower segment 206 fully extended (e.g., Figure 2). However, if the lumen is relatively small, such that the inner lumen circumference is less than the maximum dimension of the fully inflated balloon 202, the lower section 206 will remain partially folded. In this manner, the balloon 202 can self-adjust to the size of the GI lumen to hold the balloon 202 in place for delivery of the fluid formulation 317, such that the same balloon 202 can be used with a wide range of lumen sizes (e.g., different inner circumferences).

[0090] The deflation valve 212 is configured to cause the deflation of the balloon 202 when the delivery of the fluid formulation 317 to the GI luminal wall or its surrounding tissue is completed. In this way, the deflation valve 212 can promote the balloon 202 to pass through the remainder of the GI tract and leave the anus of the subject. In the illustrated embodiment, the deflation valve 212 is configured as a degradable plug, which temporarily covers the opening leading to the interior 202a. The degradable plug can be configured to degrade in response to contact with the fluid (e.g., body fluid) in the GI tract, thereby allowing the gas contained in the interior 202a to leave through the opening. For example, the deflation valve 212 can be formed by or include an enteric material. The balloon 202 can include an optional winglet 228, which can temporarily cover the deflation valve 212 until the balloon 202 expands, thereby preventing the premature activation (e.g., degradation) of the deflation valve 212. For example, flap 228 can be temporarily held (e.g., adhered, stapled, or otherwise held) in folded position 228' about flap fold axis 228a. Expansion of balloon 202 can cause flap 228 to unfold from folded position 228' to expose deflation valve 212 and allow fluid in the GI tract to reach deflation valve 212 and cause deflation valve 212 to degrade, thereby providing an opening for gas to allow deflation.

[0091] The deflation valve 212 is shown as being located on the deflation section 205, but according to other embodiments, the deflation valve 212 can be located elsewhere on the expandable member 202. In addition, the balloon 202 can include more than one deflation valve 212. The deflation valve 212 can be configured differently. Figure 2 For example, in other embodiments, the deflation valve 212 can be configured as a degradable and / or removable cover disposed over an opening in the balloon 202. In these embodiments, degradation of the cover and / or movement away from the opening can cause gas to vent from the interior 202a through the opening, thereby allowing deflation.

[0092] Reactant reservoir 214 is arranged in interior 202a, and is configured to keep first reactant 215 therein and temporarily prevent first reactant 215 from contacting second reactant 217, and this second reactant 217 is arranged in interior 202a separately.First reactant 215 can be, for example, citric acid.Second reactant 217 can be, for example, carbonate, such as potassium bicarbonate.In other embodiments, first reactant 215 and second reactant 217 can be other types of reactants (for example, acid and alkali), which cause formation to be enough to expand sacculus 202 when mixing.Second reactant 217 is shown as being arranged in interior 202a at the inflation section 204 near first reactant 215.In other embodiments, first reactant 215 and second reactant 217 can be included in other regions of sacculus 202, as long as first reactant 215 and second reactant 217 are temporarily separated from each other.

[0093] Reactant reservoir 214 is limited to the internal volume for accommodating first reactant 215. Reactant reservoir 214 can take various forms and shapes, such as sacculus or other structures. Reactant reservoir 214 is communicated with inner 202a selective fluid via reactant conduit 218 and release 216. Release 216 is connected to reactant conduit 218 so that when activating (for example, degrading) release 216, first reactant 215 can leave and enter inner 202a from reactant reservoir 214 via reactant conduit 218. For example, release 216 can be the form of degradable plug, and the inner part of this degradable plug blocking reactant conduit 218 temporarily prevents first reactant 215 from entering inner 202a. When the fluid in GI tract contacts release 216 (for example, when shell 102 and / or outer coating 104 degrade), release 216 can be degraded subsequently to allow reactant conduit 218 to discharge first reactant 215 into inner 202a.

[0094] In other embodiments, the device 200 includes a clip, a band or other structure for holding a portion of the balloon 202 in such a manner that a separate chamber for accommodating the first reactant 215 and the second reactant 217 separately and separately is temporarily defined in the interior 202a. For example, a portion of the balloon 202 can be clamped or compressed by a degradable clip or band to temporarily define a separate chamber in the interior 202a. The chambers can be substantially sealed from each other to substantially prevent the first reactant 215 and the second reactant 217 from mixing. The clip or band can be located on the outer portion of the balloon 202 so that exposure to fluid in the GI tract (e.g., when the shell 102 and / or the outer coating 104 degrades) can cause degradation of the clip or band and subsequent release from the balloon 202. When the clip or band or the like is released from the balloon 202, the separated chambers are no longer substantially sealed from each other, thereby allowing the first reactant 215 to mix with the second reactant 217 in the interior 202a.

[0095] Combining the first reactant 215 with the second reactant 217 within the interior 202a causes a chemical reaction, resulting in the formation of a gas (e.g., CO2). The gas causes the balloon 202 to expand to an expanded state within the GI lumen, resulting in the elongated segment 210 being substantially aligned with the surface of the GI lumen wall. The substantial alignment of the elongated segment 210 relative to the GI lumen wall can advantageously help facilitate the delivery of the fluid formulation 317 from the delivery assembly 300 to the GI lumen wall or surrounding tissues thereof.

[0096] Still reference Figure 2 , delivery assembly 300 is coupled to balloon 202 and at least partially disposed within interior 202a. Delivery assembly 300 is shown to include housing 302 (an embodiment of housing 112), membrane 315 (an embodiment of membrane 114), fluid formulation 317 (an embodiment of fluid formulation 116), piston 319 (an embodiment of piston 118), and needle 320 (an embodiment of needle 120). Membrane 315 and piston 319 cooperatively define a reservoir 315a for containing fluid formulation 317.

[0097] As described below, the gas pressurizing the balloon 202 can pass through the opening of the housing 302 to apply pressure to the membrane 315 on the piston 319. When the gas pressure reaches a threshold value (e.g., when the balloon 202 in the GI lumen is fully or partially expanded), the pressure causes the piston 319 and the needle 320 to move relative to the housing 302 toward the GI lumen wall. In response to the resistance applied to the needle 320 from the GI lumen wall, the piston 318 moves axially relative to the needle 320 so that the needle 320 pierces the seal on the piston 319, thereby allowing the fluid preparation 317 to flow from the reservoir 315a to the needle 320. When the seal is pierced, the gas pressure further advances the needle 320 into the GI lumen wall or surrounding tissue. The gas pressure also causes the membrane 315 to discharge the fluid preparation 317 from the reservoir 315a through the needle 320 and into the GI lumen wall or surrounding tissue.

[0098] refer to Figure 3 , a detailed view of a portion of the device 200 including the delivery assembly 300 is shown. Figure 3 As shown, delivery assembly 300 includes housing 302, needle seal 304, release mechanism 306, reservoir seal 307, membrane 315, fluid formulation 317, piston 319, needle 320, piston seal holder 321, and piston seal 323. In the illustrated embodiment, needle 320 is defined by needle sleeve 322, tissue piercing member 324, and seal piercing member 326. In other embodiments, needle 320 can be a unitary structure including needle sleeve 322, tissue piercing member 324, and seal piercing member 326.

[0099] The housing 302 includes a housing peripheral wall 302a that defines a piston chamber 302a' and a needle chamber 302a". The piston 319 is movably (eg, slidably) disposed in the piston chamber 302a'. A portion of the needle 320 (eg, the tissue piercing member 324) is disposed in the needle chamber 302a". Figure 3 In the orientation shown, the needle chamber 302a" extends from the upper end of the piston chamber 302a'. The housing 302 is configured to be coupled (e.g., heat sealed, adhered) to the balloon 202 (e.g., coupled to the piston chamber 302a') along the housing peripheral wall 302a at the transition between the piston chamber 302a' and the needle chamber 302a". Figure 3210). In the assembled state, a portion of the housing peripheral wall 302a located above the piston chamber 302a' extends outward from the elongated section 210 of the balloon 202 for positioning the needle chamber 302a" near the GI luminal wall. The piston chamber 302a' and the needle chamber 302a" both have a substantially cylindrical shape and cooperatively define a longitudinal axis 302ab for axial movement of the piston 319 and the needle 320 along it. However, it should be recognized that according to other embodiments, the piston chamber 302a' and the needle chamber 302a" may have different shapes other than cylindrical (e.g., oval, spherical). The housing 302 may further define one or more vent ports to serve as a pressure relief for the piston chamber 302a' or the balloon interior 202a during or after axial movement of the piston 319 relative to the housing 302. The vent port may be configured to allow selective fluid communication between the piston chamber 302a' and the balloon interior 202a and the GI luminal environment outside the device 200.

[0100] The needle seal 304 is connected (e.g., adhered) to the housing peripheral wall 302a at the upper end of the needle chamber 302a" to substantially prevent fluid in the GI tract from entering the needle chamber 302a" until the needle 320 (e.g., tissue piercing member 324) pierces the needle seal 304. The needle seal 304 can be formed from a penetrable material (e.g., aluminum foil) to allow the needle 320 to pierce the needle seal 304. In this way, the needle seal 304 and the housing peripheral wall 302a can cooperatively define a substantially sterile environment within the needle chamber 302a" for accommodating the needle 320 prior to delivering the fluid formulation 317 into the GI luminal wall or surrounding tissue.

[0101] The release mechanism 306 (eg, actuator, trigger) is coupled (eg, press-fit, snap-fit, adhered) to or integrally formed with the housing 302 within the piston chamber 302a'. Figure 3 As shown, the release mechanism 306 is coupled to the inner surface of the housing peripheral wall 302a within the piston chamber 302a'. As discussed below, the release mechanism 306 is configured to engage with the piston 319 to substantially prevent advancement of the piston 319 and the needle 320 until the gas within the interior 202a of the balloon 202 generates sufficient pressure. For example, Figure 5 Shown along Figure 3 A cross-sectional view of the release mechanism 306 is shown taken along line 5-5 in FIG. Figure 5As shown, the release mechanism 306 has a generally circular cross-sectional shape and includes one or more fingers 306a extending radially inwardly toward the longitudinal axis 302ab. Each of the fingers 306a extends radially inwardly from the circumferential edge of the release mechanism 306 to a free end located adjacent to the piston 319 in a cantilevered manner. As discussed below, the fingers 306a are configured to be connected to the projection 319c of the piston 319 via an interference (e.g., overlap) condition to substantially prevent the needle 320 from piercing the needle seal 304 until sufficient pressure is generated in the interior 202a. When the internal gas pressure reaches a threshold value (e.g., when the balloon 202 is fully or partially expanded), the projection 319c overcomes the interference condition with the fingers 306a by deflecting the fingers 306a away from the piston 319, thereby allowing the piston 319 to move axially toward the needle seal 304 along the longitudinal axis 302ab, so that the tissue piercing member 324 pierces the needle seal 304.

[0102] According to other embodiments, the release mechanism can be defined by a removable connection between the piston 319 and the housing 302. For example, the delivery assembly 300 can include a rear cover coupled to the housing 302. The rear cover can include one or more snap features that engage with complementary features on the piston 319 to temporarily retain the piston 319 relative to the housing 302 until the gas within the interior 202a of the balloon 202 generates sufficient pressure.

[0103] In another example, the rear cover can have a frangible (e.g., breakable) connection with the piston 319, which can be configured to disengage in response to a threshold gas pressure generated within the interior 202a to allow axial movement of the piston 319 relative to the housing 302.

[0104] The piston 319 is movably (e.g., slidably) coupled to the housing 302. Figure 3 In the unactuated state shown, the piston 319 is disposed in the piston chamber 302a'. The piston 319 includes a piston peripheral wall 319a, which defines a fluid chamber 319a' and a needle chamber 319a". As discussed below, the membrane 315 is connected to the piston 319 such that the membrane 315 surrounds the fluid chamber 319a' to define a reservoir 315a for containing a fluid agent 317 therein. The piston 319 is configured to move axially relative to the housing 302 in response to a threshold gas pressure applied to an outer surface of the membrane 315. The piston peripheral wall 319a further defines a fill port 319a'" for filling the reservoir 315a with the fluid agent 317.

[0105] After (partially or completely) filling the reservoir 315a, the fill port 319a'" is substantially fluid-sealed by, for example, heat staking the shell peripheral wall 302a to substantially block the fill port 319a'". In other embodiments, a separate seal (e.g., silicone or aluminum foil) may be coupled to the shell peripheral wall 302a at the fill port 319a'". In other embodiments, the fill port 319a'" may include a septum (e.g., a silicone septum) such that the fill port 319a'" may self-seal after filling the reservoir 315a with the fluid formulation 317.

[0106] In any case, the reservoir 315a can be filled with the fluid formulation 317 before the piston 319 is coupled to the housing 302 and the balloon 202. This can advantageously allow for flexibility associated with the aseptic assembly of the device 200. For example, before the piston 319 is assembled with the housing 302 and the balloon 202, a vacuum can be applied to the reservoir 315a via the fill port 319a'" in a sterile environment to substantially evacuate the reservoir 315a. The evacuated reservoir 315a can then be filled with the fluid formulation 317 via the fill port 319a'" in a sterile environment before being assembled with the housing 302 and the balloon 202.

[0107] Still reference Figure 3 The piston peripheral wall 319a further defines a stop feature 319b that extends from the inner surface of the piston peripheral wall 319a toward the longitudinal axis 302ab within the needle cavity 319a". The stop feature 319b is configured to engage with a complementary feature on the needle 320 (at Figure 3 326c) engages to limit the axial travel of the piston 319 relative to the needle 320, details of which will be referred to below. Figure 4 Have a discussion.

[0108] The piston peripheral wall 319a further defines a protrusion 319c extending from the outer surface of the piston peripheral wall 319a at an upper portion of the needle cavity 319a". Figure 3 In the unactuated state shown, the protrusion 319c is positioned adjacent to the release mechanism 306 below the finger 306a of the release mechanism 306. Figure 5 As discussed, protrusion 319c engages finger 306a to substantially prevent needle 320 from advancing through needle seal 304 until the internal pressure generated by the gas within interior 202a reaches a threshold value. For example, the threshold pressure can be associated with a fully inflated state of balloon 202 within the GI lumen to ensure that elongated section 210 is substantially aligned with the GI lumen wall before needle 320 is advanced from housing 302.

[0109] The reservoir seal 307 is connected (e.g., adhered) to the inner surface of the piston peripheral wall 319a to define a substantially fluid-tight seal between the fluid chamber 319a' and the needle chamber 319a". In this manner, the reservoir seal 307 substantially prevents the fluid formulation 317 from entering the needle chamber 319a", until the needle 320 pierces the reservoir seal 307. The reservoir seal 307 can be formed from a penetrable material such as aluminum foil.

[0110] The piston seal 323 is connected to the outer portion of the piston peripheral wall 319a by the piston seal retainer 321. The piston seal retainer 321 is connected (e.g., adhered, snap-fitted) to the upper portion of the piston peripheral wall 319a to hold the piston seal 323 relative to the piston 319. In other embodiments, the piston seal 323 can be integrally formed (e.g., insert molded) with the outer peripheral side of the piston 319 or otherwise connected to the outer peripheral side of the piston 319. The piston seal 323 is configured to engage the inner surface of the housing peripheral wall 302a to produce a substantially liquid-tight seal between the piston 319 and the housing peripheral wall 302a in the piston chamber 302a'. The piston seal 323 is further configured to allow relative axial movement between the piston 319 and the housing 302. The piston 319 can be formed of a polymer material (e.g., acrylonitrile butadiene styrene (ABS)) or other materials or combinations of materials. The piston seal 323 can be formed of silicone or other suitable materials.

[0111] Still reference Figure 3 , the membrane 315 is coupled to the piston 302 to define a reservoir 315a. For example, the membrane 315 can be coupled to the piston 319 by heat sealing, ultrasonic welding, adhesion, or by other means. In the illustrated embodiment, the membrane 315 is coupled to the inner surface of the piston peripheral wall 319a, which defines the fluid chamber 319a'. The membrane 315 extends circumferentially around the piston 319 to close the fluid chamber 319a'. In this way, the membrane 315, the piston peripheral wall 319a, and the reservoir seal 307 cooperate to contain the fluid formulation 317 in the reservoir 315a. The reservoir 315a can be defined to hold a volume for accommodating up to about 250μl or more of fluid, as described above with reference to Figure 1For example, the reservoir 315a can define a volume for accommodating about 50 μl to about 200 μl of fluid (including 50 μl to 250 μl of fluid, such as 50 μl, 100 μl, 150 μl, or 200 μl (or any value therebetween) of fluid, or can accommodate 200 μl or 250 μl (or any value therebetween) of fluid. As discussed below, the membrane 315 is configured to deform (e.g., bend, flex, contract) in response to gas pressure generated within the balloon 202 (from the reaction of the first reactant 215 and the second reactant 217) to discharge the fluid formulation 317 from the reservoir 315a to the needle 320. The membrane 315 can have a surface profile in a relaxed state (i.e., when the reservoir 315a is not filled with the fluid formulation 317) that is The profile is complementary to the inner surface profile of the piston 319 that defines the fluid chamber 319a'. For example, the fluid chamber 319a' can be used as a mold for forming the film 315 to vacuum form the film 315 so that the film 315 substantially simulates the inner surface profile of the fluid chamber 319a'. In this way, the film 315 can be fully deformed to discharge the major part of the fluid preparation 317 from the reservoir 315a. In addition, this complementary shape of the film 315 can help to promote the sufficient emptying of the reservoir 315a, so as to fill with the fluid preparation 317 during assembly subsequently. The film 315 can be formed by a combination of a flexible polymer material (e.g., polyethylene terephthalate (PET)) or other flexible materials or materials with sufficiently low moisture permeability and air permeability to be used with the fluid preparation 317.

[0112] The needle 320 is movably (eg, slidably) coupled to the piston 319 and disposed in the needle cavity 319a". Figure 3 In the illustrated embodiment, needle (320) is collectively defined by needle sleeve (322), tissue piercing member (324), and seal piercing member (326). In other embodiments, needle (320) is a unitary structure including needle sleeve (322), tissue piercing member (324), and seal piercing member (326).

[0113] The needle sleeve 322 couples the tissue piercing member 324 to the seal piercing member 326. In addition, the needle sleeve 322 is used to movably couple the needle 320 to the piston 319 within the needle cavity 319a". In the illustrated embodiment, the needle sleeve 322 has a hollow cylindrical shape defining a needle sleeve first end 322a and an opposing needle sleeve second end 322b. The outer surface of the needle sleeve 322 engages with the inner surface of the piston peripheral wall 319a within the needle cavity 319a" to define a substantially fluid-tight seal between the needle sleeve 322 and the piston peripheral wall 319a. In this manner, the needle sleeve 322 can help prevent the fluid formulation 317 from passing through the needle cavity 319a″ between the needle 320 and the piston peripheral wall 319a, so that a large amount of the fluid formulation 317 can be introduced from the reservoir 315a through the needle 320. The needle sleeve 322 is also configured to allow relative axial movement between the piston 319 and the needle 320 along the longitudinal axis 302ab. The needle sleeve 322 can be formed of, for example, silicone or other suitable materials.

[0114] The tissue piercing member 324 is coupled (e.g., press fit, adhered) to the needle sleeve 322 at the needle sleeve first end 322a. The tissue piercing member 324 extends outward from the needle sleeve 322. The tissue piercing member 324 includes a tapered section 324a (e.g., a pointed end) configured to pierce the needle seal 304 and penetrate the GI luminal wall in response to sufficient axial movement of the piston 319. The tissue piercing member 324 can have a length sufficient to penetrate the GI luminal wall into the peritoneum or peritoneal cavity of the subject to deliver the fluid preparation 317 therein. The free end (e.g., the pointed end) of the tapered section 324a defines the first end of the needle 320. The tapered section 324a defines a needle opening 324a' extending through the tapered section 324a for discharging the fluid preparation 317 into the GI luminal wall or surrounding tissue. The tissue piercing member 324 also includes an elongated section 324b extending from the tapered section 324a. The elongated section 324b can be coupled to the tapered section 324a or formed integrally with the tapered section 324a. A portion of the elongated section 324b is disposed in the needle sleeve 322 at the needle sleeve first end 322a. The elongated section 324b defines a first needle channel 324b' extending from the needle opening 324a' to the opposite end of the elongated section 324b.

[0115] In other embodiments, the tissue-piercing member 324 includes a side opening (e.g., a slotted opening) for discharging the fluid formulation 317 into the GI luminal wall or surrounding tissue. Figure 7-Figure 8 , according to another example, a tissue piercing member 724 (an embodiment of the tissue piercing member 324) is shown. Figure 7-Figure 8As shown, tissue piercing member 724 includes a tapered section 724a (e.g., frustoconical) extending from elongated section 724b to a distal end or tip. Tapered section 724a includes a slotted opening 724a' extending through the sidewall of tapered section 724a to an internal passage 724b' of elongated section 724b. Slotted opening 724a' is defined by a recessed portion extending transversely through the sidewall of tapered section 724a, resulting in a through hole extending to internal passage 724b'. Slotted opening 724a' is positioned offset from the central axis and tip of tissue piercing member 724 to help avoid obstruction of slotted opening 724a' by body tissue or fluid that may accumulate therein when tissue piercing member 724 penetrates the GI luminal wall or surrounding tissue.

[0116] The concave portion of the slotted opening 724a' extending transversely through the side wall of the tapered section 724a can advantageously help guide the fluid formulation in a substantially longitudinal direction (as indicated by the Figure 8 The directional arrow 726 in the figure indicates) passes through the tissue piercing member 724, thereby avoiding significantly changing the flow path through the internal channel 724b'. In this way, the fluid preparation can be effectively discharged into the GI luminal wall or its surrounding tissue via the tissue piercing member 724.

[0117] Still reference Figure 7-Figure 8 , tissue piercing member 724 also includes a tip 725 coupled to (e.g., bonded to) or integrally formed with (e.g., insert molded into) tapered section 724a. Tip 725 defines the outermost distal end of tissue piercing member 724. Tip 725 is configured to pierce the GI lumen wall or surrounding tissue. Tip 725 can be formed of a harder material than the material of tissue piercing member 724. For example, tip 725 can be formed of or include magnesium, metal, or another material or combination of materials.

[0118] The tissue-piercing members 324, 724 may be at least partially or fully degradable such that at least a portion of the tissue-piercing members 324, 724 may substantially degrade within the GI lumen wall (or other location in the GI tract) upon delivery of the fluid formulation 317. For example, the tissue-piercing members 324, 724 may be formed of or otherwise include polyethylene oxide (PEO), magnesium, or other degradable material or combination of materials.

[0119] Reference again Figure 3, the seal piercing member 326 is coupled to (e.g., press fit, adhered) the needle sleeve 322. In the illustrated embodiment, the seal piercing member 326 is configured as a substantially cylindrical member having a generally elongated configuration, although other shapes and configurations are contemplated according to other embodiments. The seal piercing member 326 extends from a seal piercing member first end 326a to an opposite seal piercing member second end 326b. The seal piercing member second end 326b defines a second end of the needle 320 positioned opposite the first end. The seal piercing member first end 326a is coupled to (e.g., press fit, adhered) the needle sleeve 322 at the needle sleeve second end 322b. The seal piercing member 326 extends outwardly from the needle sleeve second end 322b and terminates at the seal piercing member second end 326b. The seal piercing member second end 326b has a tapered profile (e.g., a pointed end) that is configured to pierce the reservoir seal 307 in response to the relative movement between the piston 319 and the needle 320. The seal piercing member 326 further defines a protrusion 326c extending outwardly (e.g., radially) from its outer surface. As discussed above and below, the protrusion 326c serves as a complementary feature for engaging with the stop feature 319b to limit the axial travel of the piston 319 relative to the needle 320. The seal piercing member 326 further defines a second needle channel 326a' for guiding the fluid preparation 317 from the reservoir 315a to the first needle channel 324b' of the tissue piercing member 324. The second needle channel 326a' extends longitudinally from the seal piercing member first end 326a to the seal piercing member second end 326b along the longitudinal axis 302ab. The seal piercing member 326 can be formed, for example, by a polymer material.

[0120] refer to Figure 4 , a portion of the device 200 including the delivery assembly 300 is shown in an actuated state after the device 200 has reached a desired location in the GI tract (e.g., the stomach or small intestine) to deliver a fluid formulation 317. Figure 6 As shown, the balloon 202 has been inflated by the gas generated within the interior 202a, so that the elongated section 210 is substantially aligned with the surface of the GI lumen wall. The gas generated within the interior 202a applies pressure (indicated by the unidirectional arrow 330) to the outer surface of the membrane 315 through the rear opening of the housing 302. When the gas pressure reaches a threshold value (e.g., a pressure associated with a fully or partially inflated state of the balloon 202), the protrusion 319c overcomes the interference condition with the release mechanism 306. As a result, the piston 319 moves axially relative to the housing 302 along the longitudinal axis 302ab toward the GI lumen wall, so that the first end of the needle 320 (e.g., the tapered section 324a) advances through the needle seal 304 to contact the GI lumen wall.

[0121] When there is sufficient resistance from the GI lumen wall acting on the needle 320, the gas pressure applied to the membrane 315 causes the piston 319 to move axially toward the GI lumen wall along the longitudinal axis 302ab relative to the needle 320. For example, the device 200 can be configured so that the piston 319 moves relative to the needle 320 when the needle 320 begins to contact the GI lumen wall to generate sufficient resistance with the lumen wall. In other embodiments, the device 200 can be configured so that the piston 319 moves relative to the needle 320 when the needle 320 penetrates to a specific depth in the GI lumen wall to generate sufficient resistance with the lumen wall. This can be achieved by, for example, selecting the material of the piston 319 and / or the needle sleeve 322 to have a sufficient coefficient of friction to control the relative movement between the piston 319 and the needle 320. In either case, the fluid formulation 317 remains in the reservoir 315a until the second end of the needle 320 (e.g., the seal piercing member second end 326b) pierces the reservoir seal 307 while the gas pressure in the balloon 202 is exerted on the membrane 315. In this manner, the delivery assembly 300 can allow for sequential timing between penetration of the GI lumen wall and discharge of the fluid formulation 317 to substantially avoid discharge of the fluid formulation 317 into the luminal environment and ensure delivery of the fluid formulation 317 into the GI lumen wall or surrounding tissue (e.g., the peritoneum or peritoneal cavity).

[0122] Due to sufficient movement of the piston 319 relative to the needle 320, the second end of the needle 320 pierces the reservoir seal 307 to allow the fluid formulation 317 to flow from the reservoir 315a to the second needle channel 326a'. The piston 319 is allowed to move axially relative to the needle 320 until the stop feature 319b engages the protrusion 326c. Upon engagement between the stop feature 319b and the protrusion 326c, the gas pressure exerted on the membrane 315 causes the piston 319 and the needle 320 to move axially relative to the housing 302 along the longitudinal axis 302ab, causing the needle 320 to further penetrate the GI luminal wall or surrounding tissue.

[0123] In addition, when piercing the reservoir seal 307, the gas pressure applied to the membrane 315 causes the membrane 315 to deform inwardly relative to the piston 319 toward the needle 320 to discharge the fluid preparation 317 from the reservoir 315a to the needle 320. Therefore, the fluid preparation 317 is guided through the second needle channel 326a', the first needle channel 324b' and the needle opening 324a', into the GI luminal wall or surrounding tissue. In this way, one or more therapeutic agents contained in the fluid preparation 317 can be delivered to the bloodstream of the experimenter to be delivered to the whole body.

[0124] After delivery of the fluid formulation 317 is completed, one or more components of the needle 320 (e.g., tissue piercing member 324) can then degrade along with one or more additional components of the device 200 (e.g., housing 302, membrane 315, piston 319) in the GI lumen wall or other areas within the GI tract. In embodiments where the needle 320 is substantially non-degradable, the device 200 is configured to retract the tissue piercing member 324 from the GI lumen wall within the housing 302 upon completion of delivery of the fluid formulation 317. For example, the device 200 can include a return spring or other biasing member coupled to the needle 320 for retracting the needle 320 within the housing 302 after delivery of the fluid formulation 317. In any of these embodiments, the deflation valve 212 can release a large amount of gas contained within the interior 202a to allow a large amount of deflation of the balloon 202 and subsequent passage of the device 200 through the remainder of the GI tract and out of the anus of the subject.

[0125] Reference now Figure 6 , a method 500 of delivering a fluid formulation 116 to a subject's GI tract using a device 100 is shown. In a first step, a subject ingests the device 100 (e.g., by swallowing the device 100) (step 501). As a result of ingestion, when the device 100 reaches a desired position in the GI tract where the fluid formulation 116 needs to be delivered, the housing 102 and / or the outer coating 104 are at least partially (or may be completely) degraded (step 502). In response to the degradation of the housing 102 and / or the outer coating 104, the release member 108 is activated to expand the expandable member 106 within the GI lumen (step 503). The expansion of the expandable member 106 within the GI lumen causes the delivery assembly 110 to be positioned close to the GI lumen wall (step 504). When the gas pressure within the expandable member 106 reaches a threshold value, the gas pressure is applied to the membrane 114 to move the piston 118 relative to the housing 112, thereby advancing the needle 120 toward the GI lumen wall (step 505). The GI lumen wall applies resistance to the needle 120, causing the piston 118 to move axially relative to the needle 120 so that the needle 120 pierces the seal on the piston 118, thereby allowing the fluid formulation 116 to flow to the needle 120 (step 506). The gas pressure within the expandable member 106 is applied to the membrane 114 to expel the fluid formulation 116 through the needle 120 and then deliver it to the GI lumen wall or its surrounding tissue (step 507). In this way, the device 100 can deliver one or more therapeutic agents contained in the fluid formulation 116 to the subject's bloodstream for delivery to the whole body.

[0126] The foregoing description of various embodiments has been presented for purposes of illustration and description. It is not intended to limit the invention to the precise form disclosed. Many modifications, variations, and improvements will be apparent to those skilled in the art. For example, embodiments of the device may be sized and otherwise adapted to various pediatric and neonatal applications and various veterinary applications. In addition, those skilled in the art will recognize or be able to determine many equivalents to the specific devices and methods described herein using only routine experimentation. Such equivalents are considered to be within the scope of this disclosure.

[0127] Although the present disclosure has been described and illustrated with reference to specific embodiments of the present disclosure, these descriptions and illustrations do not limit the present disclosure. It is clearly understood that various changes can be made and equivalent components can be replaced within the embodiments without departing from the true spirit and scope of the present disclosure as defined by the appended claims. Similarly, components, characteristics or actions from one embodiment can be easily recombined or replaced with one or more components, characteristics or actions from other embodiments to form many additional embodiments within the scope of the present invention. In addition, in various embodiments, components shown or described as being combined with other components can exist as independent components. In addition, for any positive description of components, characteristics, ingredients, features, steps, etc., embodiments of the present invention also specifically consider excluding the components, values, characteristics, ingredients, features, steps, etc. The illustrations may not necessarily be drawn to scale. Due to variables such as manufacturing processes, there may be differences between the technical reproduction in the present disclosure and the actual device. There may be other embodiments of the present disclosure that are not specifically shown. The specification and drawings should be regarded as illustrative rather than restrictive. Modifications can be made to adapt specific situations, materials, material compositions, methods or processes to the purpose, spirit and scope of the present disclosure. All such modifications are intended to fall within the scope of the appended claims. Although the methods disclosed herein have been described with reference to specific operations performed in a specific order, it is understood that these operations may be combined, subdivided, or reordered to form equivalent methods without departing from the teachings of the present disclosure. Therefore, unless otherwise specifically noted herein, the order and grouping of operations are not limitations of the present disclosure.

Claims

1. A delivery assembly for an ingestible device for delivering a fluid formulation into a GI luminal wall or surrounding tissue of a subject, the delivery assembly comprising: a housing defining a chamber; a piston movably disposed in the chamber; a needle coupled to the piston; and A membrane is coupled to the piston such that the membrane and the piston cooperatively define a reservoir for containing the fluid formulation.

2. The delivery assembly of claim 1, wherein: The piston defines a needle cavity, and wherein the needle is slidably coupled to the piston in the needle cavity.

3. The delivery assembly of claim 2, further comprising a seal coupled to the piston between the needle cavity and the reservoir to define a substantially fluid-tight seal between the needle cavity and the reservoir.

4. The delivery assembly of claim 3, wherein: The needle includes a first end configured to penetrate the GI tube lumen wall and a second end configured to pierce the seal in response to resistance applied to the needle from the GI tube lumen wall.

5. The delivery assembly of claim 1, wherein: The needle is configured to penetrate through the GI lumen wall into the peritoneum or peritoneal cavity of the subject for discharging the fluid formulation in the peritoneum or peritoneal cavity.

6. The delivery assembly of claim 1, wherein: The membrane has a surface profile that is complementary to an inner surface profile of the piston defining the reservoir.

7. The delivery assembly of claim 1, wherein: The reservoir defines a volume for containing up to about 250 μl of fluid.

8. The delivery assembly of claim 1, wherein: The reservoir defines a volume for containing about 50 μl to about 200 μl of fluid.

9. The delivery assembly of claim 1, wherein: The housing is configured to be coupled to and disposed within the expandable member.

10. The delivery assembly of claim 1, wherein: The piston is configured to move relative to the housing in response to pressure exerted on the membrane to advance the needle into the GI lumen wall.

11. The delivery assembly of claim 1, wherein: The membrane comprises a flexible material to allow the membrane to deform due to pressure applied to an outer surface of the membrane to discharge the fluid formulation from the reservoir into the needle.

12. The delivery assembly of claim 1, wherein: The piston includes a fill port for filling the reservoir with the fluid formulation.

13. The delivery assembly of claim 1, further comprising a fluid formulation disposed in the reservoir, wherein the fluid formulation comprises at least one therapeutic agent.

14. The delivery assembly of claim 13, wherein: The at least one therapeutic agent is selected from one or more of an immunosuppressive drug, a chemotherapeutic drug, a central nervous system (CNS) drug, an anti-diabetic drug, an enzyme replacement therapy (ERT) drug, an antibody, a hormone, insulin, an incretin or a combination thereof, or an oligonucleotide.

15. An ingestible device for delivering a fluid formulation into a GI lumen wall or surrounding tissue of a subject, the ingestible device comprising: Extensible components; and a delivery assembly coupled to and disposed within the expandable member, wherein the delivery assembly comprises: a housing defining a chamber; a piston movably disposed in the chamber; a needle coupled to the piston; a membrane coupled to the piston such that the membrane and the piston cooperatively define a reservoir; and A fluid formulation is disposed in the reservoir, the fluid formulation comprising at least one therapeutic agent.

16. The device according to claim 15, wherein: The expandable member includes a balloon.

17. The device of claim 15, further comprising an ingestible housing, wherein the expandable member and the delivery assembly are disposed within the ingestible housing.

18. The apparatus of claim 15, further comprising a plurality of reactants disposed within the expandable member for generating gas pressure to expand the expandable member within the GI lumen.

19. The device according to claim 18, wherein: The generated gas pressure is applied to the membrane to cause the piston to move axially relative to the housing.

20. The device according to claim 18, wherein The piston defines a needle cavity, and wherein the needle is slidably coupled to the piston in the needle cavity.

21. The device according to claim 20, wherein: The delivery assembly also includes a seal coupled to the piston between the needle lumen and the reservoir to define a substantially fluid-tight seal between the needle lumen and the reservoir.

22. The device according to claim 21, wherein The needle includes a first end configured to penetrate the GI tube lumen wall and a second end configured to pierce the seal in response to resistance applied to the needle from the GI tube lumen wall.

23. The device according to claim 22, wherein: The membrane comprises a flexible material such that the generated gas pressure deforms the membrane to expel the fluid formulation through the needle when the needle pierces the seal.

24. The device according to claim 22, wherein: The device is configured such that the first end of the needle penetrates the GI lumen wall before the second end of the needle pierces the seal.

25. The device according to claim 22, wherein: The device is configured such that penetration of the GI lumen wall by the first end of the needle occurs substantially simultaneously with piercing of the seal by the second end.

26. The device according to claim 15, wherein: The needle is configured to penetrate through the GI lumen wall into the peritoneum or peritoneal cavity of the subject to discharge the fluid formulation in the peritoneum or peritoneal cavity.

27. The device according to claim 15, wherein: The membrane has a surface profile that is complementary to an inner surface profile of the piston defining the reservoir.

28. The device according to claim 15, wherein: The reservoir defines a volume for containing up to about 250 μl of fluid.

29. The device according to claim 15, wherein: The reservoir defines a volume for containing about 50 μl to about 200 μl of fluid.

30. The device according to claim 15, wherein: The piston includes a fill port for filling the reservoir with the fluid formulation.

31. The device according to claim 15, wherein: The at least one therapeutic agent is one or more of an immunosuppressive drug, a chemotherapeutic drug, a central nervous system (CNS) drug, an anti-diabetic drug, an enzyme replacement therapy (ERT) drug, an antibody, a hormone, insulin, an incretin or a combination thereof, or an oligonucleotide.

32. An ingestible device comprising: a tissue-piercing member having an elongated section and a tapered section extending from the elongated section to a distal end; wherein the elongated section defines a longitudinal opening extending therethrough; wherein the tapered section defines a slotted opening extending through a side wall of the tapered section to the longitudinal opening; and Wherein, the slotted opening is used to discharge the fluid preparation from the tissue piercing member.

33. The device according to claim 32, wherein: The tissue-piercing member also includes a tip coupled to or integrally formed with the tapered section at the distal end.

34. The device according to claim 33, wherein The tip comprises a material that is harder than a material of the tissue-piercing member.

35. A method of delivering a fluid formulation into the GI lumen wall or surrounding tissue of a subject in need thereof, the method comprising ingesting by the subject an ingestible device according to any one of claims 15-31.

36. Use of an ingestible device according to any one of claims 15-31 for delivering a fluid formulation comprising a therapeutic agent to the GI lumen wall or surrounding tissue of a subject in need thereof.

37. A method of preparing an ingestible device for delivering a therapeutic agent into the GI lumen wall or surrounding tissue of a subject, the method comprising filling a fluid formulation comprising the therapeutic agent into a delivery assembly according to any one of claims 1-14.

38. A delivery assembly in an ingestible device for delivering a fluid formulation to the GI tract of a subject, the delivery assembly comprising: a housing defining a chamber; a piston movably disposed in the chamber; a needle coupled to the piston; and a membrane coupled to the piston such that the membrane and the piston cooperatively define a reservoir for containing the fluid formulation.

39. A device for delivering a fluid formulation into the GI tract of a subject, the device comprising: Extensible components; and a delivery assembly coupled to and disposed in the expandable member, the delivery assembly comprising: a housing defining a chamber; a piston movably disposed in the chamber; a needle coupled to the piston; and a membrane coupled to the piston such that the membrane and the piston cooperatively define a reservoir for containing the fluid formulation.

40. A method for delivering a fluid formulation to the GI tract of a subject, comprising an ingestion device, wherein the device comprises an expandable member and a delivery assembly coupled to and disposed within the expandable member, the delivery assembly comprising: a housing defining a chamber; a piston movably disposed in the chamber, the piston defining a needle cavity; a needle coupled to the piston and disposed in the needle cavity; a membrane coupled to the piston such that the membrane and the piston cooperatively define a reservoir containing the fluid formulation; and a seal coupled to the piston to define a substantially fluid-tight seal between the needle chamber and the reservoir; wherein gas is generated within the expandable member to expand the expandable member within the GI lumen, thereby positioning the delivery assembly adjacent to the GI lumen wall; wherein gas pressure is applied to the membrane to advance the needle from the housing toward the GI lumen wall; wherein the piston moves relative to the needle to cause the needle to pierce the seal and allow the fluid formulation to flow from the reservoir to the needle in response to resistance applied to the needle from the GI lumen wall; and wherein upon piercing the seal, the gas pressure causes the membrane to expel the fluid formulation from the reservoir, through the needle, and into the GI lumen wall or surrounding tissue thereof.